◆英語タイトル:Teva Pharmaceuticals USA Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013913
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月22日
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Teva Pharmaceuticals USA Inc (Teva Pharmaceuticals), formerly Lemmon Pharmacal Company, a subsidiary of Teva Pharmaceutical Industries Ltd, is a developer and manufacturer of pharmaceutical ingredients. The company’s products include antiulcer agents and acid suppressants, antiviral capsules, analgesics, anti-glaucoma agents, tamsulosin hydrochloride, losartan potassium, contraceptives, antacid tablets, laxatives, anti-inflammatory drugs, antibacterial injection, corticosteroids, hydrochlorothiazide, dorzolamide hydrochloride ophthalmic solutions and pramipexole dihydrochloride. It also provides generic drugs and over-the-counter healthcare products. The company also commercializes products through wholesalers, retail chains, distributors and government agencies. It operates through its offices in the US and Israel. Teva Pharmaceuticals is headquartered in North Wales, Pennsylvania, the US.
Teva Pharmaceuticals USA Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Teva Pharmaceuticals USA Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Teva Pharmaceuticals USA Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Teva Pharmaceuticals USA Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Teva Pharmaceuticals USA Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Teva Pharmaceuticals USA Inc, Medical Devices Deals, 2011 to YTD 2017 9
Teva Pharmaceuticals USA Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Teva Pharmaceuticals USA Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Cephalon To Acquire Assets Related To Larazotide Acetate From Alba Therapeutics 12
Venture Financing 13
SymBio Pharma Secures US$24.5 Million In Series E Financing Round 13
Private Equity 14
Partners In Life Sciences Acquires Manufacturing Facility In Mitry-Mory From Cephalon 14
Partnerships 15
Champions Biotech Enters Into An Agreement With Cephalon 15
Celator Pharma Extends Research Agreement With Cephalon 16
Licensing Agreements 17
Teva Pharma Enters into Licensing Agreement with CSPC Zhongqi Pharma 17
Checkpoint Therapeutics Enters into Licensing Agreement with Cephalon 18
Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma 19
Lundbeck Enters Into Licensing Agreement With Cephalon 20
APP Pharma Enters Into Licensing Agreement With Teva Pharma For Gemcitabine HCI 21
ImmunGene Enters Into Licensing Agreement With Cephalon 22
Asset Transactions 23
Ignyta Acquires Four Oncology R&D Assets from Cephalon 23
ANI Pharma Acquires ANDA from Teva Pharma 25
ANI Pharma Acquires 22 Generic Drug Products from Teva Pharma 26
Amedra Pharmaceuticals Acquires Mebendazole Tablet Product from Teva Pharmaceutical 27
Acquisition 28
Ind-Swift Lab May Sell Stake in Company 28
Teva Completes Acquisition Of Cephalon For US$6,800 Million 29
Cephalon Acquires 91.73% Stake In ChemGenex 31
Cephalon Acquires Gemin X Pharma 33
Cephalon Completes Acquisition Of 20% Stake In Mesoblast 35
Teva Pharmaceuticals USA Inc – Key Competitors 37
Teva Pharmaceuticals USA Inc – Key Employees 38
Teva Pharmaceuticals USA Inc – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Legal and Regulatory 40
Jun 22, 2017: Wockhardt and its Subsidiaries settle with Teva and its Affiliate a commercial litigation in the High Court, London 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41
List of Tables
Teva Pharmaceuticals USA Inc, Pharmaceuticals & Healthcare, Key Facts 2
Teva Pharmaceuticals USA Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Teva Pharmaceuticals USA Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Teva Pharmaceuticals USA Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Teva Pharmaceuticals USA Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Teva Pharmaceuticals USA Inc, Medical Devices Deals, 2011 to YTD 2017 9
Teva Pharmaceuticals USA Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Cephalon To Acquire Assets Related To Larazotide Acetate From Alba Therapeutics 12
SymBio Pharma Secures US$24.5 Million In Series E Financing Round 13
Partners In Life Sciences Acquires Manufacturing Facility In Mitry-Mory From Cephalon 14
Champions Biotech Enters Into An Agreement With Cephalon 15
Celator Pharma Extends Research Agreement With Cephalon 16
Teva Pharma Enters into Licensing Agreement with CSPC Zhongqi Pharma 17
Checkpoint Therapeutics Enters into Licensing Agreement with Cephalon 18
Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma 19
Lundbeck Enters Into Licensing Agreement With Cephalon 20
APP Pharma Enters Into Licensing Agreement With Teva Pharma For Gemcitabine HCI 21
ImmunGene Enters Into Licensing Agreement With Cephalon 22
Ignyta Acquires Four Oncology R&D Assets from Cephalon 23
ANI Pharma Acquires ANDA from Teva Pharma 25
ANI Pharma Acquires 22 Generic Drug Products from Teva Pharma 26
Amedra Pharmaceuticals Acquires Mebendazole Tablet Product from Teva Pharmaceutical 27
Ind-Swift Lab May Sell Stake in Company 28
Teva Completes Acquisition Of Cephalon For US$6,800 Million 29
Cephalon Acquires 91.73% Stake In ChemGenex 31
Cephalon Acquires Gemin X Pharma 33
Cephalon Completes Acquisition Of 20% Stake In Mesoblast 35
Teva Pharmaceuticals USA Inc, Key Competitors 37
Teva Pharmaceuticals USA Inc, Key Employees 38
Teva Pharmaceuticals USA Inc, Other Locations 39
Teva Pharmaceuticals USA Inc, Subsidiaries 39